Uncategorized
Abnormal ERGs reversed to normal in patients treated with Jetrea
SEATTLE — Full-field electroretinograms in patients treated with ocriplasmin changed normally, and treated patients with abnormal ERGs reversed to normal by 2 years, according to a poster presented here. The OASIS phase 3b clinical trial assessed long-term outcomes in patients with symptomatic vitreomacular adhesion (VMA), and this substudy evaluated “the relationship of ERG changes with anatomic and visual outcomes for up to 24 months after a single injection of ocriplasmin 0.125 mg,” Joseph I. Markoff, MD, said at the Association for Research in Vision and Ophthalmology meeting.